Neogen Chemicals

Who are the top shareholders of the Neogen Chemicals?

The top shareholders of Neogen Chemicals include Haridas Thakarshi Kanani, who holds 39.44%, mutual funds with 20.24%, foreign institutional investors at 7.79%, and individual investors owning 12.89%. The SBI Large & Midcap Fund is the largest public shareholder with 7.69%.

The top shareholders of Neogen Chemicals include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Haridas Thakarshi Kanani, owning 39.44% of the company. Additionally, mutual funds collectively hold 20.24% through 15 different schemes, while foreign institutional investors (FIIs) account for 7.79% with 64 FIIs involved. The highest public shareholder is the SBI Large & Midcap Fund, which holds 7.69%. Individual investors also have a notable presence, holding 12.89% of the shares.

What does Neogen Chemicals do?

Neogen Chemicals Ltd is a manufacturer of bromine-based compounds, lithium and bromine salts, and grignard chemicals in the specialty chemicals sector. As of March 2025, it reported net sales of ₹203 Cr and a net profit of ₹2 Cr, with a market cap of ₹4,398 Cr.

Overview:<BR>Neogen Chemicals Ltd is a leading manufacturer of bromine-based compounds, lithium and bromine salts, and grignard chemicals, operating in the specialty chemicals industry within the small-cap market.<BR><BR>History:<BR>Neogen Chemicals Limited was incorporated as a Private Limited Company on March 7, 1989, in Thane, Maharashtra. It was converted to a Public Limited Company and renamed on July 2, 1998. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 203 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 2 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 4,398 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 99.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.12%<BR>- Debt-Equity: 0.75<BR>- Return on Equity: 5.58%<BR>- Price to Book: 5.55<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

Has Neogen Chemicals declared dividend?

Neogen Chemicals Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of September 19, 2024. The dividend yield is 0.12%, and while recent total returns have fluctuated, the company has shown significant growth over the past five years.

Neogen Chemicals Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.12%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -23.16%, with a dividend return of 0%, resulting in a total return of -23.16%.<BR><BR>Over the past year, the price return was 10.39%, the dividend return was 0.13%, leading to a total return of 10.52%.<BR><BR>In the 2-year period, the price return was 4.32%, with a dividend return of 0.31%, culminating in a total return of 4.63%.<BR><BR>For the 3-year period, the price return was 13.7%, the dividend return was 0.59%, which resulted in a total return of 14.29%.<BR><BR>In the last 4 years, the price return was 85.69%, with a dividend return of 1.18%, giving a total return of 86.87%.<BR><BR>Over the past 5 years, the price return was 259.73%, the dividend return was 2.25%, leading to a total return of 261.98%.<BR><BR>Overall, Neogen Chemicals has declared a dividend, and while the recent total returns have varied, the long-term performance shows significant growth, particularly over the 5-year period. The dividend yield remains modest, reflecting a balance between price appreciation and dividend distribution.

Who are the peers of the Neogen Chemicals?

Neogen Chemicals' peers include Epigral, Balaji Amines, Styrenix Perfor., Camlin Fine, Laxmi Organic, Rossari Biotech, Vishnu Chemicals, S H Kelkar & Co., Foseco India, and Nocil. In terms of management risk, growth, and returns, Camlin Fine leads with a 1-year return of 141.62%, while Neogen Chemicals has a return of -0.02%.

Peers: The peers of Neogen Chemicals are Epigral, Balaji Amines, Styrenix Perfor., Camlin Fine, Laxmi Organic, Rossari Biotech, Vishnu Chemicals, S H Kelkar & Co., Foseco India, and Nocil.<BR><BR>Quality Snapshot: Excellent management risk is observed at Styrenix Perfor. and Foseco India, while Good management risk is found at Epigral, Neogen Chemicals, Rossari Biotech, Vishnu Chemicals, and the rest. Average management risk is seen at Balaji Amines, Laxmi Organic, S H Kelkar & Co., and Nocil, while Below Average management risk is noted at Camlin Fine. In terms of Growth, Excellent growth is seen at Styrenix Perfor. and the rest have Below Average growth, except for Rossari Biotech and Vishnu Chemicals, which have Average growth. Capital Structure ratings show Excellent at Balaji Amines, Laxmi Organic, and Foseco India, Good at Epigral, Vishnu Chemicals, and S H Kelkar & Co., while Neogen Chemicals, Camlin Fine, and the rest have Below Average.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Camlin Fine at 141.62%, while the lowest is Nocil at -37.94%. Neogen Chemicals has a 1-year return of -0.02%, which is significantly better than Nocil but worse than Camlin Fine. Additionally, the peers with negative six-month returns include Neogen Chemicals, Rossari Biotech, and Laxmi Organic.

Who are in the management team of Neogen Chemicals?

As of March 2023, the management team of Neogen Chemicals includes Haridas Thakarshi Kanani (Chairman & Executive Director), Harin Haridas Kanani (Managing Director), and several independent and non-executive directors, along with Unnati Kanani as Company Secretary. The team combines executive and non-executive roles to oversee the company's governance and management.

As of March 2023, the management team of Neogen Chemicals includes the following individuals:<BR><BR>1. Haridas Thakarshi Kanani - Chairman & Executive Director<BR>2. Harin Haridas Kanani - Executive Director / Managing Director / Promoter<BR>3. Anurag Surana - Non-Executive & Non-Independent Director<BR>4. Sanjay N Mehta - Independent Non-Executive Director<BR>5. Hitesh Bharatkumar Reshamwala - Independent Non-Executive Director<BR>6. Shyamsundar Radheshyam Upadhyay - Executive Director & Whole-time Director<BR>7. Ranjan Kumar Malik - Independent Non-Executive Director<BR>8. Avi Kersi Sabavala - Independent Non-Executive Director<BR>9. Unnati Kanani - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive and non-executive directors, contributing to the governance and management of the company.

How big is Neogen Chemicals?

As of 24th July, Neogen Chemicals Ltd has a market capitalization of 4,132.00 Cr, with net sales of 777.56 Cr and a net profit of 34.85 Cr for the latest four quarters. The company reported shareholder's funds of 760.29 Cr and total assets of 1,461.40 Cr for the annual period ending March 2024.

As of 24th July, Neogen Chemicals Ltd has a market capitalization of 4,132.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Neogen Chemicals reported net sales of 777.56 Cr and a net profit of 34.85 Cr.<BR><BR>For the latest annual period ending March 2024, the company had shareholder's funds amounting to 760.29 Cr and total assets of 1,461.40 Cr.

How has been the historical performance of Neogen Chemicals?

Neogen Chemicals has shown consistent growth in net sales, increasing from 306.12 Cr in Mar'20 to 777.56 Cr in Mar'25, despite fluctuations in profit margins and rising raw material costs. Total assets grew significantly, while cash flow from operating activities improved to 195.00 Cr in Mar'25, indicating resilience in its financial performance.

Answer:<BR>The historical performance of Neogen Chemicals shows a consistent growth trend in net sales and profits over the years, with some fluctuations in profit margins.<BR><BR>Breakdown:<BR>Neogen Chemicals has demonstrated significant growth in net sales, increasing from 306.12 Cr in Mar'20 to 777.56 Cr in Mar'25. The total operating income followed a similar trajectory, rising from 306.12 Cr in Mar'20 to 777.56 Cr in Mar'25. However, the raw material costs also increased, reaching 506.08 Cr in Mar'25, which impacted the operating profit, which was 136.32 Cr in Mar'25 compared to 110.05 Cr in Mar'24. The profit before tax showed some volatility, peaking at 70.93 Cr in Mar'23 but dropping to 49.96 Cr in Mar'25. Profit after tax also experienced fluctuations, with a high of 49.87 Cr in Mar'23 and a decrease to 34.63 Cr in Mar'25. The company's total assets grew from 354.85 Cr in Mar'20 to 1,747.31 Cr in Mar'25, while total liabilities increased from 354.85 Cr to 566.04 Cr in the same period. The cash flow from operating activities improved significantly to 195.00 Cr in Mar'25, contrasting with negative cash flow in previous years. Overall, Neogen Chemicals has shown resilience and growth in its financial metrics, despite some challenges in profit margins and costs.

Is Neogen Chemicals technically bullish or bearish?

As of November 10, 2025, Neogen Chemicals is in a bearish trend with strong weakness indicated by bearish MACD and Bollinger Bands signals, despite a mildly bullish KST signal.

As of 10 November 2025, the technical trend for Neogen Chemicals has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. Key indicators driving this assessment include bearish signals from both the MACD and Bollinger Bands on weekly and monthly time frames, alongside a bearish moving average on the daily chart. The Dow Theory also reflects a mildly bearish outlook on both weekly and monthly levels. Despite the KST showing a mildly bullish signal weekly, the overall technical picture remains negative, particularly given the significant decline in stock performance relative to the Sensex over multiple time frames.

Is Neogen Chemicals overvalued or undervalued?

As of November 24, 2025, Neogen Chemicals is considered overvalued with a valuation grade of expensive, highlighted by a PE ratio of 86.07, significantly higher than peers like Godrej Industries and Deepak Nitrite, and a poor year-to-date return of -47.89% compared to the Sensex's 8.65% gain.

As of 24 November 2025, the valuation grade for Neogen Chemicals has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 86.07, an EV to EBITDA of 30.31, and a Price to Book Value of 3.80. <BR><BR>When compared to peers, Neogen's PE ratio significantly exceeds that of Godrej Industries, which stands at 35.62, and Deepak Nitrite at 41.71, both of which are categorized as expensive. The recent stock performance has been notably poor, with a year-to-date return of -47.89%, contrasting sharply with the Sensex's gain of 8.65% during the same period, reinforcing the overvaluation narrative.

Are Neogen Chemicals Ltd latest results good or bad?

Neogen Chemicals Ltd's latest results show strong revenue growth with a record ₹220.02 crores for Q3 FY26, but a concerning 63.14% drop in net profit and rising costs indicate significant financial challenges, suggesting investors should be cautious.

Neogen Chemicals Ltd's latest results present a mixed picture, with significant concerns overshadowing some positive aspects. On one hand, the company achieved its highest-ever quarterly revenue of ₹220.02 crores for Q3 FY26, reflecting a year-on-year growth of 9.23% and a sequential increase of 5.44%. This demonstrates resilience in revenue generation.<BR><BR>However, the profitability metrics are troubling. The net profit for the quarter dropped sharply by 63.14% year-on-year to just ₹3.69 crores, indicating a significant decline in profitability. The operating margin also contracted to 14.50%, down 270 basis points from the previous year, which suggests rising costs and pricing pressures that the company has struggled to manage.<BR><BR>Moreover, interest costs surged by 60.16% year-on-year, further eroding profitability and highlighting the company's heavy debt burden. The interest coverage ratio has fallen to a concerning 1.48 times, indicating that the company is barely generating enough operating profit to cover its interest expenses.<BR><BR>Overall, while Neogen Chemicals has shown strong revenue growth, the sharp decline in net profit, rising costs, and high debt levels signal a challenging financial situation. Investors should approach the company's outlook with caution, given these significant red flags.

When is the next results date for Neogen Chemicals Ltd?

The next results date for Neogen Chemicals Ltd is 16 May 2026.

The next results date for Neogen Chemicals Ltd is scheduled for 16 May 2026.

Should I buy, sell or hold Neogen Chemicals Ltd?

Which are the latest news on Neogen Chemicals?

Why is Neogen Chemicals Ltd falling/rising?

As of 24-May, Neogen Chemicals Ltd's stock price is slightly declining at 1,688.50, following a trend of losses over the past two days. This downturn is driven by negative financial results, high debt levels, and decreased investor interest, despite a strong year-to-date performance.

As of 24-May, Neogen Chemicals Ltd's stock price is experiencing a slight decline, currently at 1,688.50, reflecting a change of -0.3 (-0.02%). This decrease follows a trend where the stock has been losing for the last two days, resulting in a total drop of -1.32% during this period. <BR><BR>Despite a positive performance over the past week, where the stock rose by 1.38% compared to the Sensex's 0.24%, and a significant year-to-date increase of 42.61% against the Sensex's decline of 11.51%, the recent downturn can be attributed to several negative factors. The company has reported negative results for the last four consecutive quarters, with a significant decline in profit after tax (PAT) of -30.32% over the latest six months. Additionally, the company's ability to service its debt is concerning, as indicated by a high Debt to EBITDA ratio of 10.16 times, which suggests financial strain.<BR><BR>Investor participation has also decreased, with delivery volume dropping by 66.19% compared to the five-day average, indicating reduced interest from investors. Furthermore, while the stock is trading above its moving averages, the overall sentiment is tempered by the company's low return on equity of 6.86% and a return on capital employed (ROCE) of just 5.25%, which points to low profitability and high valuation concerns. <BR><BR>In summary, the combination of declining investor participation, poor financial performance, and high debt levels is contributing to the stock's recent fall.